-
Mashup Score: 012-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT - 8 month(s) ago
August 30, 2023 — BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro Missiondrug-eluting stent (DES) compared to Resolute Onyx DES (p
Source: www.dicardiology.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
March 5, 2023 — In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure using a clip to repair the valve was safe, cut the rate of hospitalizations for heart failure by 47% and reduced deaths from any cause by almost 30% after five years of follow-up, according to a study presented at the American College of Cardiology’s Annual Scientific Session…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @ACCinTouch @AbbottCardio #COAPT trial demonstrates long-term benefits of #transcatheter procedure in high-risk patients with #heartfailure, presented during #latebreaker at #ACC23: https://t.co/VqiO3C2Co6
-
-
Mashup Score: 2VIDEO: Clinical Science in Structural Heart Disease - 2 year(s) ago
At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women’s Interventional Cardiology Health Initiative; and Associate Professor, Harvard Medical School, moderated a late-breaker session on Clinical Science in Structural Heart Disease. Here, she highlights the key results of the clinical trials for DAIC/dicardiology.com. Related TCT 2022 Coverage: VIDEO:…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @TCTConference @BWHCVImaging At #TCT2022, #JaneLeopold, MD, a #cardiologist at Brigham and Women’s Hospital moderated a #latebreaker session on Clinical Science in Structural #HeartDisease; watch the #video: https://t.co/e1gzRWkuNd
-
-
Mashup Score: 0VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial - 2 year(s) ago
At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital, presented a late-breaker session on Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertensions: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial. He spoke with DAIC editors about the outcomes. Related TCT 2022 Coverage:…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @TCTMD @BWHCVImaging At #TCT2022, #Deepak_Bhatt, MD, MPh, presented a #latebreaker session on the 3-Year Follow-up of the #SYMPLICITY #HTN_3 Trial. He spoke with DAIC editors about the outcomes: https://t.co/qNYHtwc016
-
-
Mashup Score: 2Distal Versus Conventional Radial Access for Coronary Angiography and Intervention (DISCO RADIAL): - 2 year(s) ago
Abstract Objectives The aim of this study was to assess the superiority of DRA compared with conventional TRA with respect to forearm RAO. Background Currently, transradial access (TRA) is the reco…
Categories: Expert Picks, Latest HeadlinesTweet-
Technique Matters! Take-home messages from #EuroPCR #LateBreaker DISCO RADIAL w/ Fernando Alfonso interviewing presenter Adel Aminian, reinforcing the benefit of the radial approach & a focus on #hemostasis. Read full publication in #JACCINT: https://t.co/kk5TKgwKjb #RadialFirst https://t.co/4JpRXqyHEW
-
-
Mashup Score: 0Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at ACC22 - 2 year(s) ago
April 3, 2022 — Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 APOLLO trial that showed SLN360, an investigational siRNA, reduced levels of lipoprotein(a) (“Lp(a)”), an important genetic…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @SilenceTheraPlc #ACC22 #LATEBREAKER: #SLN360 reduced Lp(a) – a key genetic risk factor for #heartdisease - by up to 98% with reductions of up to 81% persisting at 150 days: https://t.co/HEMqWjfkNa
-
-
Mashup Score: 0JAK1 inhibitor induces clinical response in UC - 3 year(s) ago
Selective janus kinase 1 inhibitor, SHR0302, induced clinical response and remission among patients with moderate to severe ulcerative colitis, according to a study at Digestive Disease Week. “JAK signaling plays an important role in the pathogenesis of UC by blocking the JAK-STAT pathway,” Min-Hu Chen, MD, PhD, The First Affiliated Hospital, Sun Yat-sen University, said.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
“Study results indicated that selective #JAK1 inhibitor SHR0302 are superior compared to placebo at induction of clinical response and clinical remission in patients with moderate to severe #UC,” Min-Hu Chen, MD, PhD, @DDWMeeting #latebreaker #DDW2021 https://t.co/pO2kueTaHF
-
-
Mashup Score: 1
Febuxostat is non-inferior to allopurinol therapy with respect to the primary cardiovascular endpoint, and its long-term use is not associated with an increased risk of death or serious adverse events compared with allopurinol.
Source: The LancetCategories: Latest Headlines, RheumatologyTweet-
Thomas Macdonald @dundeeuni presents results of the FAST trial just published in @TheLancet https://t.co/ZDddJ3A5AI #ACR20 #latebreaker Plus linked comment > https://t.co/4uu19wRHuO https://t.co/BlowuOaYsK
-
@DAICeditor @BIOTRONIK_US @escardio Non-inferiority and safety of one-month #DAPT with #BIOTRONIK’s drug-eluting #stent presented as #latebreaker at ESC 2023: https://t.co/GO9eEssdPF #ESC23 #ESC2023